Literature DB >> 18706412

Mechanisms of ErbB receptor negative regulation and relevance in cancer.

William H D Fry1, Lakmal Kotelawala, Colleen Sweeney, Kermit L Carraway.   

Abstract

The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706412      PMCID: PMC2667444          DOI: 10.1016/j.yexcr.2008.07.022

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  97 in total

1.  Neuregulin-induced expression of the acetylcholine receptor requires endocytosis of ErbB receptors.

Authors:  Xiao-Li Yang; Yang Z Huang; Wen C Xiong; Lin Mei
Journal:  Mol Cell Neurosci       Date:  2005-02       Impact factor: 4.314

2.  Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling.

Authors:  Edith Kario; Mina D Marmor; Konstantin Adamsky; Ami Citri; Ido Amit; Ninette Amariglio; Gideon Rechavi; Yosef Yarden
Journal:  J Biol Chem       Date:  2004-12-07       Impact factor: 5.157

3.  Characterization of human LNX, a novel ligand of Numb protein X that is downregulated in human gliomas.

Authors:  Juxiang Chen; Jian Xu; Wei Zhao; Guohan Hu; Haipeng Cheng; Ying Kang; Yi Xie; Yicheng Lu
Journal:  Int J Biochem Cell Biol       Date:  2005-04-11       Impact factor: 5.085

4.  Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.

Authors:  Hu Xu; Yingjie Yu; Dorota Marciniak; Arun K Rishi; Fazlul H Sarkar; Omer Kucuk; Adhip P N Majumdar
Journal:  Mol Cancer Ther       Date:  2005-03       Impact factor: 6.261

5.  Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.

Authors:  Julia A Staverosky; Leslie L Muldoon; Shuhua Guo; Adam J Evans; Edward A Neuwelt; Gail M Clinton
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

6.  The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor.

Authors:  J K Doherty; C Bond; A Jardim; J P Adelman; G M Clinton
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

7.  Decorin prevents metastatic spreading of breast cancer.

Authors:  Charles C Reed; Anna Waterhouse; Siobhan Kirby; Paul Kay; Rick T Owens; David J McQuillan; Renato V Iozzo
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

8.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Authors:  Cary D Austin; Ann M De Mazière; Paul I Pisacane; Suzanne M van Dijk; Charles Eigenbrot; Mark X Sliwkowski; Judith Klumperman; Richard H Scheller
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

9.  The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.

Authors:  Melanie B Laederich; Melanie Funes-Duran; Lily Yen; Ellen Ingalla; Xiuli Wu; Kermit L Carraway; Colleen Sweeney
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

10.  Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype.

Authors:  Costanza Ballarò; Sara Ceccarelli; Cecilia Tiveron; Laura Tatangelo; Anna Maria Salvatore; Oreste Segatto; Stefano Alemà
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

View more
  21 in total

Review 1.  E3 ubiquitin ligases in ErbB receptor quantity control.

Authors:  Kermit L Carraway
Journal:  Semin Cell Dev Biol       Date:  2010-09-22       Impact factor: 7.727

2.  EGFs and ERBBs--brief history and prospects.

Authors:  David F Stern
Journal:  Semin Cell Dev Biol       Date:  2010-10-21       Impact factor: 7.727

3.  The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3.

Authors:  Jason Hatakeyama; Jessica H Wald; Hanine Rafidi; Antonio Cuevas; Colleen Sweeney; Kermit L Carraway
Journal:  Sci Signal       Date:  2016-06-28       Impact factor: 8.192

4.  MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis.

Authors:  Yoo-Seung Ko; Jeong A Bae; Keon Young Kim; Sung Jin Kim; Eun Gene Sun; Kyung Hwa Lee; Nacksung Kim; Hyuno Kang; Young-Woo Seo; Hangun Kim; Ik Joo Chung; Kyung Keun Kim
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

5.  Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.

Authors:  Justyna A Janas; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

6.  Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.

Authors:  William H D Fry; Catalina Simion; Colleen Sweeney; Kermit L Carraway
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

7.  Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.

Authors:  Ellen Q Ingalla; Jamie K Miller; Jessica H Wald; Heather C Workman; Rouminder P Kaur; Lily Yen; William H D Fry; Alexander D Borowsky; Lawrence J T Young; Colleen Sweeney; Kermit L Carraway
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

8.  The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.

Authors:  Sharleen V Menezes; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

9.  A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation.

Authors:  Yuri Frosi; Sergio Anastasi; Costanza Ballarò; Giulia Varsano; Loriana Castellani; Elena Maspero; Simona Polo; Stefano Alemà; Oreste Segatto
Journal:  J Cell Biol       Date:  2010-04-26       Impact factor: 10.539

10.  Transformation of polarized epithelial cells by apical mistrafficking of epiregulin.

Authors:  Bhuminder Singh; Galina Bogatcheva; Mary Kay Washington; Robert J Coffey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.